U.S. markets open in 7 hours 57 minutes

Axovant Gene Therapies Ltd. (AXGT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.2100-0.1100 (-3.31%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close3.3200
Open3.2800
Bid0.0000 x 1400
Ask0.0000 x 1400
Day's Range3.1600 - 3.3550
52 Week Range1.4100 - 8.0800
Volume334,129
Avg. Volume247,545
Market Cap129.479M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.7790
Earnings DateAug 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.57
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Axovant Announces Corporate Updates and Financial Results for First Fiscal Quarter Ended June 30, 2020

    * Data readouts for AXO-Lenti-PD and AXO-AAV-GM1 remain on-track for Q4 2020 * Completed 3-year manufacturing and supply agreement with Oxford BioMedica for AXO-Lenti-PD * Company had $55.5 million of cash and cash equivalents as of June 30, 2020NEW YORK and BASEL, Switzerland, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage gene therapy company developing innovative gene therapies for neurodegenerative diseases, today provided financial results for its first fiscal quarter ended June 30, 2020.“During our first fiscal quarter, we continued to make significant progress across our three clinical-stage gene therapy development programs in Parkinson’s disease, GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases and remain on-track for key data readouts later this year,” said Pavan Cheruvu, M.D., Chief Executive Officer of Axovant. “Notably this quarter, we completed Type II (Juvenile) patient enrollment in the low dose cohort of our dose-escalation study of AXO-AAV-GM1 and have begun preparations to initiate treatment of Type I (infantile) GM1 later this year. Additionally, our gene therapy manufacturing strategy has meaningfully progressed as we extended our supply collaboration with Oxford BioMedica around a new scalable, suspension-based manufacturing process to support our clinical studies and future commercialization of AXO-Lenti-PD. In the coming months, we look forward to presenting program updates across each of our three clinical-stage programs and will work tirelessly to execute our strategy on behalf of patients, families, caregivers and our shareholders.”Key Highlights and Development UpdatesAXO-Lenti-PD gene therapy for Parkinson’s disease * Completed enrollment of the second dose cohort with the enrollment of four patients and remain on-track to deliver 6-month safety and efficacy data in Q4 2020. * Entered into a clinical supply and manufacturing agreement with Oxford BioMedica to produce clinical trial material at-scale to support randomized, controlled Phase 2 and Phase 3 clinical studies and eventual commercialization. * Anticipated completion of the first batch of AXO-Lenti-PD manufactured using a suspension-based process by year-end 2020. * Enrollment of the first subject in a randomized, sham-controlled Phase 2 study of AXO-Lenti-PD anticipated in 2021. * Presented an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in May 2020 summarizing the mechanistic rationale and development status of AXO-Lenti-PD by Gregory Stewart, Ph.D., SVP, Scientific Affairs.AXO-AAV-GM1 gene therapy for GM1 gangliosidosis * Enrolled five Type II (juvenile) patients in the low-dose cohort of Stage 1 of the registrational study with 6-month safety and efficacy data expected in Q4 2020. * Expanded protocol through successful IND amendment to enable dosing of Type I (infantile) patients and to explore a higher dose of 4.5 x 1013 vg/kg in both infantile and juvenile patients. * Enrollment of both Type I and Type II patients at the low and high-dose cohorts expected to continue throughout the second half of 2020. * Presented an oral presentation at the ASGCT Annual Meeting in May 2020 demonstrating the superior efficacy of intravenous GM1 gene therapy administration in the feline model from collaborator Amanda Gross from Auburn University (Poster 495). AXO-AAV-GM2 gene therapy for Tay-Sachs and Sandhoff disease * Company-sponsored investigational new drug (IND) application clearance is expected in Q4 2020. * Presented clinical and preclinical data at the ASGCT Annual Meeting in May 2020 highlighting the mechanistic rationale for gene replacement in Tay-Sachs/Sandhoff disease and preliminary evidence of safety and efficacy from a first-in-human gene therapy study in Tay-Sachs disease.  -  Oral presentation on clinical data from two children treated in an expanded access clinical trial for the first-in-human gene therapy trial for Tay-Sachs Disease reported by Terence Flotte, M.D., Provost & Executive Deputy Chancellor, University of Massachusetts Medical School and Principal Investigator (Poster 1299). -  Poster presentation on the surgical technique for bilateral intrathalamic infusion of rAAVrh8-HEXA/HEXB gene therapy in an infant with Tay-Sachs Disease from collaborator Oguz Cataltepe, M.D., Professor, University of Massachusetts Medical School and Director of Pediatric Neurosurgery, UMass Memorial Medical Center (Poster 666). -  Oral presentation on preclinical data from intravenous AAV gene therapy demonstrating improved lifespan and clinical metrics in feline Sandhoff Disease from collaborator Anne Maguire from Auburn University (Poster 493).Corporate Updates * Axovant continues its corporate transformation to align corporate structure and governance with current and future business activity. Specific changes intended to occur by March 31, 2021 include: -  Redomiciliation to Delaware from Bermuda -  Plans to initiate a corporate name change of Axovant Gene Therapies Ltd. -  Transition of the Board of Directors to a majority of independent membersFirst Fiscal Quarter Financial SummaryFor the first fiscal quarter ended June 30, 2020, research and development expenses were $5.2 million, a decrease of $15.9 million compared to the prior year quarter. Excluding a development milestone of $13.0 million achieved and due to our partner, Oxford BioMedica (UK) Ltd., in the prior year quarter, research and development expenses decreased by $2.9 million, primarily related to the termination of our legacy AXO-AAV-OPMD program in September 2019.General and administrative expenses for the first fiscal quarter ended June 30, 2020 were $4.6 million, a decrease of $1.9 million compared to the prior year quarter, primarily due to reductions in (i) personnel costs of $0.8 million and share-based compensation expense of $0.4 million attributable to reduced headcount and (ii) pharmaceutical market research costs of $0.6 million.Net loss for the first fiscal quarter ended June 30, 2020 was $8.6 million, or $0.20 per share, compared to a net loss of $28.1 million, or $1.23 per share, in the prior year quarter. Net cash used in operating activities was $13.5 million for the first fiscal quarter ended June 30, 2020.As of June 30, 2020, we had $55.5 million of cash and cash equivalents. The Company holds no short-term or long-term debt on the balance sheet. We expect the cash and cash equivalents to sustain our operations into the second calendar quarter of 2021.About AxovantAxovant Gene Therapies is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurodegenerative diseases. Our current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis (also known as Tay-Sachs disease and Sandhoff disease), and Parkinson’s disease. Axovant is focused on accelerating product candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations. For more information, visit www.axovant.com.Forward-Looking StatementsThis press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “intended”, "may," "might," "will," "would," "should," "expect," "believe," "estimate," and other similar expressions are intended to identify forward-looking statements. For example, all statements Axovant makes regarding costs associated with its operating activities are forward-looking. All forward-looking statements are based on estimates and assumptions by Axovant’s management that, although Axovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Axovant expected. Such risks and uncertainties include, among others, the impact of the Covid-19 pandemic on our operations, the initiation and conduct of preclinical studies and clinical trials; the availability of data from clinical trials; the scaling up of manufacturing, the expectations for regulatory submissions and approvals; the continued development of our gene therapy product candidates and platforms; Axovant’s scientific approach and general development progress; and the availability or commercial potential of Axovant’s product candidates. These statements are also subject to a number of material risks and uncertainties that are described in Axovant’s most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 11, 2020, as updated by its subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. Axovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.Contacts:Media Parag Meswani Axovant Gene Therapies Ltd. (212) 547-2523 media@axovant.comInvestors and AnalystsDavid Nassif Axovant Gene Therapies Ltd. Chief Financial Officer and General Counsel (646) 677-6770 investors@axovant.com AXOVANT GENE THERAPIES LTD. Condensed Consolidated Statements of Operations (Unaudited, in thousands, except share and per share amounts) Three Months Ended June 30,  2020 2019 Operating expenses:    Research and development expenses    (includes $563 and $721 of share-based compensation expense for the three months ended June 30, 2020 and 2019, respectively)$5,194   $21,090   General and administrative expenses    (includes $1,027 and $1,414 of share-based compensation expense for the three months ended June 30, 2020 and 2019, respectively)4,640   6,468   Total operating expenses9,834   27,558   Other (income) expenses:    Interest expense796   1,558   Other income(2,066) (1,097) Loss before income tax expense(8,564) (28,019) Income tax expense30   38   Net loss$(8,594) $(28,057) Net loss per common share — basic and diluted$(0.20) $(1.23) Weighted-average common shares outstanding — basic and diluted43,287,222   22,780,114   AXOVANT GENE THERAPIES LTD. Condensed Consolidated Balance Sheets (Unaudited, in thousands, except share and per share amounts) June 30, 2020 March 31, 2020 Assets    Current assets:    Cash and cash equivalents$55,482  $80,752  Prepaid expenses and other current assets3,998  2,971  Income tax receivable1,717  1,707  Total current assets61,197  85,430  Long-term investment8,055  5,871  Other non-current assets46  46  Operating lease right-of-use assets1,105  1,532  Property and equipment, net633  801  Total assets$71,036  $93,680       Liabilities and Shareholders’ Equity     Current liabilities:    Accounts payable$2,970  $4,412  Accrued expenses8,949  11,319  Current portion of operating lease liabilities465  889  Current portion of long-term debt—  15,423  Total current liabilities12,384  32,043  Operating lease liabilities, net of current portion71  79  Total liabilities12,455  32,122       Shareholders’ equity:    Common shares, par value $0.00001 per share, 1,000,000,000 shares authorized, 40,973,380 and 39,526,299 issued and outstanding at June 30, 2020 and March 31, 2020, respectively—  —  Additional paid-in capital825,830  820,257  Accumulated deficit(767,238) (758,644) Accumulated other comprehensive loss(11) (55) Total shareholders’ equity58,581  61,558  Total liabilities and shareholders’ equity$71,036  $93,680

  • The Daily Biotech Pulse: Sanofi-GSK Land $2.1B Funding For Coronavirus Vaccine, D-Day For GW Pharma, FDA Nod For Roche
    Benzinga

    The Daily Biotech Pulse: Sanofi-GSK Land $2.1B Funding For Coronavirus Vaccine, D-Day For GW Pharma, FDA Nod For Roche

    Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 30) * Achieve Life Sciences Inc (NASDAQ: ACHV) * Annexon Inc (NASDAQ: ANNX) (IPOed July 24) * Atossa Therapeutics Inc (NASDAQ: ATOS) * Bio-Rad Laboratories, Inc. (NYSE: BIO) * Bio-Rad Laboratories, Inc. Class B (NYSE: BIO-B) * Catalent Inc (NYSE: CTLT) * Dr.Reddy's Laboratories Ltd (NYSE: RDY * Edesa Biotech Inc (NASDAQ: EDSA)(announced filing of an IND for a Phase 2/3 study of a COVID treatment candidate) * Hologic, Inc. (NASDAQ: HOLX) * Horizon Therapeutics PLC (NASDAQ: HZNP) * Immunic Inc (NASDAQ: IMUX) * Ligand Pharmaceuticals Inc. (NASDAQ: LGND) * Merit Medical Systems, Inc. (NASDAQ: MMSI) * NeoGenomics, Inc. (NASDAQ: NEO) * OraSure Technologies, Inc. (NASDAQ: OSUR) * Penumbra Inc (NYSE: PEN) * Precipio Inc (NASDAQ: PRPO)( announced a distribution agreement for its FDA-authorized COVID-19 serology antibody tests) * Repligen Corporation (NASDAQ: RGEN) * TIZIANA LF SCIE/S ADR (NASDAQ: TLSA) * Veracyte Inc (NASDAQ: VCYT) * Zoetis Inc (NYSE: ZTS)Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 30) * Acorda Therapeutics Inc (NASDAQ: ACOR) * Genfit SA (NASDAQ: GNFT) * Gritstone Oncology Inc (NASDAQ: GRTS) * Happiness Biotech Group Ltd (NASDAQ: HAPP) * Orchard Therapeutics PLC - ADR (NASDAQ: ORTX) * ORIC Pharmaceuticals Inc (NASDAQ: ORIC) * Pandion Therapeutics Holdco LLC (NASDAQ: PAND) * RA Medical Systems Inc (NYSE: RMED) * Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) * Tricida Inc (NASDAQ: TCDA) * Verrica Pharmaceuticals Inc (NASDAQ: VRCA)Stocks In Focus Pfizer/BioNTech Agrees to Supply 120M Doses of Coronavirus Vaccine to Japan Pfizer Inc. (NYSE: PFE) and BioNTech SE - ADR (NASDAQ: BNTX) announced an agreement with the Ministry of Health, Labour and Welfare in Japan to supply 120 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, subject to clinical success and regulatory approval, beginning in the first half of 2021.The companies have already signed agreements with the U.K. and U.S. governments for supplying BNT162.Tiziana Applies For Patent For Nasal Administration of its Monoclonal Antibody as a Potential COVID-19 Cure Tiziana said it has submitted a patent application for the potential use of nasally administered Foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of COVID-19, either alone or in combination with other anti-viral drugs.The stock was soaring 47.53% to $7.30 in pre-market trading Friday.Roche's Combo Therapy Gets FDA Nod For Skin Cancer Roche Holdings AG (OTC: RHHBY) said the FDA approved Tecentriq plus Cotellic and ZelboraF for the treatment of BRAF V600 mutation-positive advanced melanoma patients.Sanofi/GSK Gets $2.1B U.S. Government Funding For COVID-19 Vaccine Supply Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NYSE: GSK) announced an agreement with the U.S. government under the Operation Warp Speed project, for up to $2.1 billion in funding, more than half of which is to support further development of the vaccine, including clinical trials, with the remainder used for manufacturing scale-up and delivery of an initial 100 million doses of the vaccine. Sanofi will receive the majority of the funding.The U.S. government has a further option for the supply of an additional 500 million doses longer term, the companies said.Axovant Announces Manufacturing Supply Agreement With U.K. Gene Therapy Company Axovant Gene Therapies Ltd (NASDAQ: AXGT) said its subsidiary has signed a three-year Clinical Supply Agreement with U.K.'s Oxford Biomedica plc, under which the latter will manufacture GMP batches for Axovant to support the ongoing and future clinical development of AXO-Lenti-PD, a clinical-stage gene therapy product to treat moderate to severe Parkinson's Disease.J&J's Psoriasis Drug Gets Label Expansion; Coronavirus Vaccine Produces Positive Results in Pre-clinical Studies Johnson & Johnson's (NYSE: JNJ) Janssen unit said the FDA approved an expanded indication for Stelara as a treatment for pediatric patients, who struggle with the skin lesions or plaques associated with moderate to severe plaque psoriasis.Separately, J&J announced publication in the journal Nature results of preclinical studies of its adenovirus serotype 26 vector-based vaccine, which showed the investigational vaccine elicited a robust immune response as demonstrated by "neutralizing antibodies," successfully preventing subsequent infection and providing complete or near-complete protection in the lungs from the virus in non-human primates. The company expects to commence Phase 3 studies in September.Earnings Corvus Pharmaceuticals Inc's (NASDAQ: CRVS) second-quarter loss narrowed from the year-ago period but was wider than the consensus estimate.The stock fell 6.32% to $4 in after-hours trading.Opko Health Inc. (NASDAQ: OPK) said its second-quarter revenues increased from $226.4 million to $301.2 million. The company reversed from a loss of 10 cents per share to a profit of 5 cents per share.View more earnings on IBBThe stock lost 6.09% to $5.55 in after-hours trading.Emergent Biosolutions Inc (NYSE: EBS) reported a 62.3% year-over-year jump in second-quarter revenues and its adjusted EPS exceeded estimates. The company raised its 2020 guidance.The shares were climbing 6.04% to $102.82.Gilead Sciences, Inc. (NASDAQ: GILD) said its second-quarter revenues fell from $5.7 billion in 2019 to $5.1 billion in 2020. The non-GAAP EPS fell from $1.72 to $1.11, missing the consensus estimate of $1.45. The company raised its product sales and EPS guidance for the full year.Gilead shares were retreating 3.43% to $69.85.DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT) reported a higher operating income for the first half but its net loss widened year-over-year.The stock was advancing 8.05% to $4.16.On The Radar PDUFA Dates GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) awaits FDA verdict on its sNDA for Epidiolex for the treatment of seizures associated with tuberous sclerosis complex.Earnings AbbVie Inc (NYSE: ABBV) (before the market open) ImmunoGen, Inc. (NASDAQ: IMGN) (before the market open) GlycoMimetics Inc (NASDAQ: GLYC) (before the market open)See more from Benzinga * The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter * The Daily Biotech Pulse: Merck's Breakthrough Therapy Designation, Sonoma Surges On Sanitizer News, Sanofi-Glaxo And More * The Daily Biotech Pulse: Spectrum's Positive Dementia Readout, Pfizer, BioNTech Start Late-Stage Coronavirus Trial, resTORbio Receives COVID-19 Funding(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • GlobeNewswire

    Axovant Signs Three-Year Clinical Supply Agreement With Oxford Biomedica for Manufacturing and Supply of AXO-Lenti-PD

    NEW YORK and BASEL, Switzerland, July 31, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, announced today that its subsidiary has signed a three-year Clinical Supply Agreement (“CSA”) with Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group. The CSA builds on the worldwide license agreement signed between the two companies in June 2018 for the Parkinson’s disease gene therapy program OXB-102, now called AXO-Lenti-PD. Under the terms of the CSA, Oxford Biomedica will manufacture GMP batches for Axovant to support the ongoing and future clinical development of AXO-Lenti-PD, a clinical-stage gene therapy product to treat moderate to severe Parkinson’s Disease based on Oxford Biomedica’s LentiVector® platform. Axovant is currently conducting the Phase 2 SUNRISE-PD trial with AXO-Lenti-PD. Dosing of all patients in the second cohort has been completed with 6-month safety and efficacy data expected in the fourth quarter of 2020. Oxford Biomedica expects to manufacture AXO-Lenti-PD in its commercial-scale GMP manufacturing facilities including Oxbox in the UK, and additionally in other OXB GMP facilities as required to ensure security of supply.“This Agreement with Oxford Biomedica means that together we can continue to advance the development of AXO-Lenti-PD in Parkinson’s disease,” said Pavan Cheruvu, Axovant Chief Executive Officer. “We are pleased to extend our partnership with Oxford Biomedica, a world leader in lentiviral vector development and manufacturing, as we scale-up AXO-Lenti-PD production to support our Phase 2 and Phase 3 clinical studies and enable commercialization of the product. This marks another mutual accomplishment for our Parkinson’s disease program where we expect to enroll the first subject in a randomized, sham-controlled trial in 2021.”John Dawson, CEO of Oxford Biomedica, added, “This new Agreement builds upon our existing worldwide licensing agreement with Axovant and highlights the strengths of Oxford Biomedica's commercial GMP manufacturing capabilities. We are pleased with how the partnership is progressing and excited by the clinical progress to date. The agreement today signals our commitment to the efficient ongoing development of this much needed product for patients with Parkinson’s disease. We are now at a stage in the partnership where we can determine the manufacturing activities and infrastructure required to support the mid and late-stage development of AXO-Lenti-PD in a way which is compatible with later commercialization and we look forward to this next phase of our partnership.”About Axovant Gene TherapiesAxovant Gene Therapies is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurodegenerative diseases. Our current pipeline of gene therapy candidates target GM1 gangliosidosis, GM2 gangliosidosis (also known as Tay-Sachs disease and Sandhoff disease), and Parkinson’s disease. Axovant is focused on accelerating product candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations. For more information, visit www.axovant.com.About AXO-Lenti-PD AXO-Lenti-PD is an investigational gene therapy for the treatment of Parkinson’s disease that is designed to deliver three genes (tyrosine hydroxylase, cyclohydrolase 1, and aromatic L-amino acid decarboxylase) via a single lentiviral vector to encode a set of critical enzymes required for dopamine synthesis, with the goal of reducing variability and restoring steady levels of dopamine in the brain. The investigational gene therapy aims to provide patient benefit for years following a single administration. The SUNRISE-PD Phase 2 trial is ongoing with dosing completed for all patients in cohort 2, with 6-month safety and efficacy data expected in Q4 2020. Axovant expects to dose the first patient in the Part B randomized, sham controlled study in 2021.About Oxford Biomedica Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a Clinical and Commercial Supply Agreement with AstraZeneca for manufacture of the adeno based COVID-19 vaccine candidate, AZN1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 550 people. Further information is available at www.oxb.com.Forward-Looking StatementsThis press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "might," "will," "would," "should," "expect," "believe," "estimate," and other similar expressions are intended to identify forward-looking statements. For example, all statements Axovant makes regarding costs associated with its operating activities are forward-looking. All forward-looking statements are based on estimates and assumptions by Axovant’s management that, although Axovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Axovant expected. Such risks and uncertainties include, among others, the impact of the Covid-19 pandemic on our operations, the initiation and conduct of preclinical studies and clinical trials; the availability of data from clinical trials; the scaling up of manufacturing, the expectations for regulatory submissions and approvals; the continued development of its gene therapy product candidates and platforms; Axovant’s scientific approach and general development progress; and the availability or commercial potential of Axovant’s product candidates. These statements are also subject to a number of material risks and uncertainties that are described in Axovant’s most recent Annual Report on Form 10- K filed with the Securities and Exchange Commission on June 10, 2020, as updated by its subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. Axovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.Contacts:Media & InvestorsParag Meswani Axovant Gene Therapies Ltd. (212) 547-2523 media@axovant.com investors@axovant.com